2013

Cancer Immunotherapy

Paradigms, Practice and Promise

Editors:

ISBN: 978-1-4614-4731-3 (Print) 978-1-4614-4732-0 (Online)

Table of contents (15 chapters)

  1. Front Matter

    Pages i-ix

  2. Overview

    1. Front Matter

      Pages 1-1

    2. No Access

      Book Chapter

      Pages 3-15

      Historical Perspectives and Current Trends in Cancer Immunotherapy

    3. No Access

      Book Chapter

      Pages 17-44

      T Cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment

  3. Passive strategies to boost anti-tumor immunity

    1. Front Matter

      Pages 45-45

    2. No Access

      Book Chapter

      Pages 47-70

      Adoptive T Cell Transfer

    3. No Access

      Book Chapter

      Pages 71-108

      Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

  4. Active strategies to boost anti-tumor immunity

    1. Front Matter

      Pages 109-109

    2. No Access

      Book Chapter

      Pages 111-146

      Peptide and Protein-Based Cancer Vaccines

    3. No Access

      Book Chapter

      Pages 147-171

      Antigen Targeting to Dendritic Cells for Cancer Immunotherapy

    4. No Access

      Book Chapter

      Pages 173-210

      Cytokines in the Treatment of Cancer

    5. No Access

      Book Chapter

      Pages 211-280

      Immune Co-signaling to Treat Cancer

    6. No Access

      Book Chapter

      Pages 281-314

      Managing Regulatory T Cells to Improve Cancer Immunotherapy

    7. No Access

      Book Chapter

      Pages 315-333

      Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives

    8. No Access

      Book Chapter

      Pages 335-376

      Antibodies as Cancer Immunotherapy

    9. No Access

      Book Chapter

      Pages 377-396

      Targeted Toxins in Cancer Immunotherapy

  5. Additional strategies and considerations

    1. Front Matter

      Pages 397-397

    2. No Access

      Book Chapter

      Pages 399-424

      Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules

    3. No Access

      Book Chapter

      Pages 425-453

      Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy

    4. No Access

      Book Chapter

      Pages 455-474

      Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies

  6. Back Matter

    Pages 475-483